Latest Life Sciences Sector News

ALS Limited has reported a robust first half for FY26, with revenue climbing 13.3% to $1.7 billion and underlying NPAT rising 17.2%, driven by strong organic growth across all business streams and strategic investments in digital innovation.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Vection Technologies reports a 60% surge in operating cash flow in Q1 FY26, driven by a landmark $22.3 million Defence framework agreement and a strategic $21 million capital raise. The company is poised for sustainable profitability with a record $75 million contract pipeline through 2028.

AnteoTech Ltd reports strong quarterly progress with a key US joint development agreement, significant manufacturing scale-up, and expanded market access in South Korea, underpinning its 2025 commercialisation strategy.

Wellnex Life Limited announces the resignation of CEO Zack Bozinovski, who will remain with the company until April 2026, while a $2.3 million loan repayment schedule is negotiated.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Vection Technologies has expanded its AI contract portfolio by securing an additional $2.1 million through a deepened exclusive partnership with Area12 Consulting, bringing total contracts since May 2025 to $5.7 million.

AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.

Vection Technologies has secured $1 million in new AI contracts, including a significant third deal with Area 12 Consulting, boosting their partnership to $3.6 million in just ten weeks.

Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

Lendlease has partnered with The Crown Estate to create a 50/50 joint venture aimed at accelerating capital recycling of over $300 million through UK commercial and residential developments. The deal also includes a $1.2 billion Australian office investment mandate, boosting Lendlease’s funds under management to $20 billion.